By a News Reporter-Staff News Editor at Life Science Weekly -- New research on Membrane Proteins is the subject of a report. According to news reporting from Beijing, People's Republic of China, by NewsRx journalists, research stated, "HER2, a member of the epidermal growth factor receptor (ErbB) family, is over-expressed in many cancers. Trastuzumab and Pertuzumab are two monoclonal antibodies targeting different extracellular domains of HER2 for cancer therapy."
The news correspondents obtained a quote from the research from the Institute of Physical Chemistry, "As Pertuzumab binds to the dimerization arm of HER2, it can block HER2 heterodimerization and in turn ErbB signaling. Whether Trastuzumab has the same function is unclear. In this work, we have applied living-cell single-molecule force spectroscopy (SMFS) by Atomic Force Microscopy (AFM) to investigate the effect of Trastuzumab, as well as Pertuzumab, on HER2-modulated EGF-EGFR interaction. The results demonstrated that EGF bound to EGFR more stably in the cells co-expressing EGFR and HER2, and the binding enhancement in the presence of HER2 was inhibited by either Trastuzumab or Pertuzumab. Trastuzumab is expected to exert a similar inhibition effect on HER2/EGFR dimerization as Pertuzumab, although it does not bind directly to the dimerization arm of HER2."
According to the news reporters, the research concluded: "Living-cell single-molecule force spectroscopy (SMFS) combined by Atomic Force Microscopy (AFM) was used by this team of scientists to investigate the effect of two monoclonal antibodies used in cancer therapy, Trastuzumab and Pertuzumab, on HER2-modulated EGF-EGFR interaction, demonstrating the utility of this technique in characterizing the effects of protein-based therapeutics on membrane receptors."
For more information on this research see: Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand-receptor interaction. Nanomedicine, 2013;9(5):627-35. (Elsevier - www.elsevier.com; Nanomedicine - www.elsevier.com/wps/product/cws_home/703416)
Our news journalists report that additional information may be obtained by contacting X. Zhang, Beijing National Laboratory for Molecular Sciences, CAS Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing, People's Taiwan. Additional authors for this research include X. Shi, L. Xu, J. Yuan and X. Fang (see also Membrane Proteins).
Keywords for this news article include: Asia, Antibodies, Beijing, Therapy, Immunology, Blood Proteins, Immunoglobulins, Protein Kinases, Membrane Proteins, Phosphotransferases, People's Republic of China, Epidermal Growth Factor Receptor, Receptor Protein Tyrosine Kinases, Gastrointestinal Hormone Receptors, Intercellular Signaling Peptides and Proteins.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC